



Application No. 10/696,268
Paper Dated March 18, 2004
Attorney Docket No. 4084-032129

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/696,268 Confirmation No. 6488
Applicant : Sang-Nyun Kim, et al.
Filed : October 29, 2003
Title : Use of 3-Position Cyclosporin Derivatives for Hair Growth
Group Art Unit : 1646
Examiner : Not Yet Assigned
Customer No. : 28289

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the requirements of 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants submit this Information Disclosure Statement together with a completed Form PTO/SB/08A and copies of the listed references.

The above-identified Patent Application is a continuation-in-part of parent United States Patent Application Serial No. 10/141,723, filed May 9, 2002.

Japanese Patent Publication Nos. 60-243008, 62-19512 and 62-19513, European Patent No. 0414632, British Patent No. 2,218,334, WO 93/17039, United States Patent No. 5,807,820 and the first 8 articles listed in the "Other Prior Art" section of Form PTO/SB/08A were submitted with Applicants' Information Disclosure Statement in parent Application Serial No. 10/141,723.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on March 18, 2004.

Kay E. Yetter
(Typed Name of Person Mailing Paper)

Kay E. Yetter
Signature

03/18/04
Date



Application No. 10/696,268
Paper Dated March 18, 2004
Attorney Docket No. 4084-032129

The following references were cited by the Examiner during the prosecution of parent Application Serial No. 10/141,723: United States Patent Nos. 4,771,122; 5,948,884; 5,994,299; and 6,521,595; United States Patent Application No. 2001/0025025 and 2002/0165133 and Seebach et al., "Modification of Cyclosporin A."

The remaining references identified on Form PTO/SB/08A are known to the Applicants.

Because this Information Disclosure Statement is being submitted before a first Office Action on the merits, it is timely under 37 C.F.R. § 1.97(b)(3) and no fee is required. The Commissioner of Patents and Trademarks is hereby authorized to charge any additional fees which may be required to Deposit Account No. 23-0650. One (1) original and two (2) copies of this Information Disclosure Statement are enclosed.

Respectfully submitted,

WEBB ZIESENHEIM LOGSDON
ORKIN & HANSON, P.C.

By 

Richard L. Byrne
Registration No. 28,498
Attorney for Applicants
700 Koppers Building
436 Seventh Avenue
Pittsburgh, PA 15219-1818
Telephone: (412) 471-8815
Facsimile: (412) 471-4094
E-mail: webblaw@webblaw.com

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2001. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/696,268
				Filing Date	October 29, 2003
				First Named Inventor	Sang Nyun KIM et al.
				Group Art Unit	1646
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	4084-032129
Sheet	2	of	2		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cite and/or country where published.	T ²
		MAURER et al., "Hair Growth Modulation by Topical Immunophilin Ligands," <u>American Journal of Pathology</u> , 1997, pp. 1433-41, Vol. 150, No. 4.	
		EBERLE et al., "Cyclosporin A: Regioselective Ring Opening and Fragmentation Reactions via Thioamides. A Route to Semisynthetic Cyclosporins," <u>J. Org. Chem.</u> , 1994, pp. 7249-7258, Vol. 59, No. 24.	
		LUTZ, "Effects of Cyclosporin A on Hair," <u>Skin Pharmacol.</u> , 1994, pp. 101-4, Vol. 7.	
		EBERLE et al., "Preparation of [D-Cysteine]-cyclosporin via Intramolecular Sulfur Transfer Reaction," <u>J. Org. Chem.</u> , 1993, pp. 673-677, Vol. 58, No. 3.	
		SEEBACH et al., "Thiocyclosporins: Preparation, Solution and Crystal Structure, and Immunosuppressive Activity," <u>Helv. Chim. Acta</u> , 1991, pp. 1953-1990, Vol. 74.	
		GILHAR et al., "Topical cyclosporine in male pattern alopecia," <u>J. Am. Acad. Dermatol.</u> , 1990, pp. 251-3, Vol. 22, No. 2.	
		GUPTA et al., "Oral cyclosporine for the treatment of alopecia areata," <u>J. Am. Acad. Dermatol.</u> , 1990, pp. 242-50, Vol. 22, No. 2.	
		VON TRABER et al., "Novel Cyclosporins from <i>Tolypocladium inflatum</i> . The Cyclosporins K-Z," <u>Helv. Chim. Acta</u> , 1987, pp. 13-36, Vol. 70.	
		YAMAMOTO et al., "Hair Growth-Stimulating Effects of Cyclosporin A and FK506, Potent Immunosuppressants," <u>Journal of Dermatological Science</u> 7 (Suppl.), 1994, pp. 547-554.	
		BOREL et al., "In Vivo Pharmacological Effects of Cyclosporin and Some Analogues," <u>Advances in Pharmacology</u> , Vol. 35, pp. 115-246, 1996, Exhibit A.	
		PAUS et al., "Hair Growth Control by Immunosuppression," <u>Arch. Dermatol. Res.</u> (1996) 288:408-410 (see in particular Table 1) (Exhibit B)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.